Lion Point Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Lion Point Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,000	Closed	-$206K	–	34
2023 Q4	$206K	Buy	+14,000	New	+$215K	0.1%	25

Other funds holding AMLX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lion Point Capital's AMLX Position: Q1 2024 in Review

Lion Point Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2024, closing a stake of 14,000 shares — an estimated $206K sold.

Lion Point Capital first reported a position in AMLX in Q4 2023 and held it in 1 quarter. The position peaked at $206K in Q4 2023. 143 funds tracked by Wall St. Rank hold AMLX as of Q1 2024.

Lion Point Capital reported no remaining Amylyx Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Lion Point Capital sold 14,000 Amylyx Pharmaceuticals shares in Q1 2024, an estimated $206K.
Lion Point Capital first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Lion Point Capital's Amylyx Pharmaceuticals position peaked at $206K in Q4 2023.
143 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2024.

Based on Lion Point Capital's 13F filing for Q1 2024, filed 15 May 2024.